Key Drivers
- Cash generation
- Low leverage
- Dilution risk
AIAI Summary
PGNY has shifted from a reliable compounder to a higher-quality earnings story after a record quarter and strong cash flow, but with the stock already re-rated, the investment now hinges on continued margin/cash delivery, real traction in Progyny Select, and control of dilution/SBC or else upside could fade quickly.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash generation
- •Low leverage
- •Dilution risk
PGNY shows strong profitability, liquidity, and cash flow with improving margins, but rising dilution and a thinner equity cushion temper the investment case.
Price Behavior
Key Price Behavior Insights:
- •Breakout held
- •Fast momentum run
- •Watch support
PGNY's last month has been constructively bullish, with a breakout from the mid-$18s into the $23s holding above the old base, though the fast gap-driven run leaves it vulnerable if $22.5-$23.0 fails.
Sharp gap-driven surge from the mid-$18s into the $23s raises short-term pullback risk
Sentiment & News
Key News Insights:
- •Revenue Beat
- •Demand Strength
- •Analyst Upgrades
Progyny's outlook improved as Q1 revenue and earnings beat expectations, demand and member engagement stayed strong, and analyst sentiment turned more bullish ahead of conference visibility and buybacks.
The news is positive for PGNY, signaling improving fundamentals and sentiment that could support the stock near term
Similar Companies in Healthcare
Other companies in the same sector with AI ratings